Inhibikase Therapeutics, Inc.
Financial highlights
| Metric | FY 12/31/25 | FY 12/31/24 | FY 12/31/23 | FY 12/31/22 | FY 12/31/21 |
|---|---|---|---|---|---|
| Income Statement | |||||
| Revenue | — | $0.0 | $0.3 | $0.1 | $3.1 |
| Operating income | -$52.0 | -$28.6 | -$20.1 | -$18.1 | -$14.8 |
| Net income | -$48.3 | -$27.5 | -$19.0 | -$18.1 | -$14.8 |
| Cash Flow Statement | |||||
| Free cash flow | -$27.8 | -$19.1 | -$18.1 | -$17.6 | -$14.3 |
Shares outstanding 139.5M · Free float 68.2%
Annual filing data through FY ended December 31, 2025; float as of September 12, 2026.